Brainomix and Medtronic Team Up to Transform Stroke Care in Western Europe

Enhancing Stroke Care Through Innovation

In an impactful move for stroke healthcare, UK-based Brainomix, renowned for its advanced AI imaging software, has joined forces with Medtronic Neurovascular, a leader in medical technology. This strategic partnership seeks to elevate stroke care across Western Europe by leveraging cutting-edge artificial intelligence (AI) solutions within hospital settings, thereby improving patient access to life-saving treatments and enhancing outcomes.

The Brainomix 360 Stroke platform utilizes state-of-the-art AI algorithms that interpret brain scans in real time. This technology aids healthcare professionals in making crucial decisions regarding treatment and patient transfer. The platform's effectiveness was substantiated by a major study involving over 450,000 patients in England over five years. Remarkably, the findings indicated that facilities utilizing Brainomix experienced a 100% increase in thrombectomy procedures compared to their peers, with an overall 37% higher uptake in treatment.

The collaboration brings together Medtronic’s extensive experience in neurovascular interventions with Brainomix’s innovative stroke imaging technology. This partnership promises significant advancements in stroke care, providing healthcare practitioners with tools to diagnose conditions more swiftly and accurately. By streamlining decision-making processes, this collaboration aims to provide timely life-saving interventions for stroke patients across the region.

Dr. Michalis Papadakis, CEO and Co-Founder of Brainomix, commented on the partnership, stating, "This collaboration is a perfect match; Medtronic's stature as a dominant provider in neurovascular devices aligns beautifully with our expertise in stroke AI imaging. Together, we can enhance stroke management across Europe and ensure more patients receive essential treatments."

Dr. Alex Solich, Senior Consultant for Neurointervention at Karolinska University Hospital in Örebro, voiced his enthusiasm for the initiative, stating, "As a physician treating strokes, I recognize the critical importance of delivering rapid and precise care. This alliance between Medtronic Neurovascular and Brainomix stands to optimize treatment workflows and significantly enhance patient recovery prospects. Being part of a shift towards data-informed decisions empowers us to advance stroke care and improve myriad patient outcomes."

Key Advantages of the Partnership

1. Regional Treatment Improvement: Medtronic’s established presence will accelerate the dissemination of Brainomix's AI technology, making innovative treatments accessible to a wider network of hospitals and healthcare providers.
2. Enhanced Diagnostic Precision: Merging Brainomix's advanced imaging software with Medtronic’s neurovascular solutions will equip health professionals with cutting-edge diagnostic capabilities, leading to more prompt and informed responses in critical situations.
3. Optimized Clinical Processes: This partnership not only seeks to expedite stroke detection and response but also aims to relieve some of the operational pressures faced by healthcare systems, enhancing overall productivity across hospital networks.

About Brainomix

Brainomix is at the forefront of AI software development, focusing on precision medicine specifically in stroke and lung fibrosis treatment. Originating from a spin-off at the University of Oxford, Brainomix operates in over 30 countries, providing revolutionary imaging solutions that enhance treatment rates and improve patient independence. With its flagship product, the Brainomix 360 stroke platform, the company has successfully integrated its advanced imaging solutions into numerous hospitals worldwide, driving significant improvements in clinical outcomes.

To discover more about Brainomix and its groundbreaking technology, visit www.brainomix.com, and follow their updates on Twitter, LinkedIn, and Facebook.